Literature DB >> 31576357

68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients.

Laura Evangelista1, Fabio Zattoni2, Pierpaolo Alongi3.   

Abstract

Entities:  

Year:  2019        PMID： 31576357      PMCID： PMC6685849          DOI： 10.21037/atm.2019.06.28

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

Review 1.  Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature.

Authors:  Gianluca Giannarini; Giuseppe Petralia; Harriet C Thoeny
Journal:  Eur Urol       Date:  2011-09-28       Impact factor: 20.096

2.  Balancing process and risk: standardizing posttreatment surveillance for renal cell carcinoma.

Authors:  Marc C Smaldone; Robert G Uzzo
Journal:  J Urol       Date:  2013-05-18       Impact factor: 7.450

Review 3.  New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Authors:  Laura Evangelista; Alberto Briganti; Stefano Fanti; Stephen Joniau; Sven Reske; Riccardo Schiavina; Christian Stief; George N Thalmann; Maria Picchio
Journal:  Eur Urol       Date:  2016-02-02       Impact factor: 20.096

4.  18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.

Authors:  Jiri Ferda; Eva Ferdova; Milan Hora; Ondrej Hes; Jindrich Finek; Ondrej Topolcan; Boris Kreuzberg
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

Review 5.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Authors:  Nicolette K Janzen; Hyung L Kim; Robert A Figlin; Arie S Belldegrun
Journal:  Urol Clin North Am       Date:  2003-11       Impact factor: 2.241

6.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

7.  Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population.

Authors:  Mudalsha Ravina; Søren Hess; Mahesh Singh Chauhan; Mattakorottu Joseph Jacob; Abass Alavi
Journal:  Clin Nucl Med       Date:  2014-09       Impact factor: 7.794

8.  Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms.

Authors:  S Choudhary; A Rajesh; N J Mayer; K A Mulcahy; A Haroon
Journal:  Clin Radiol       Date:  2009-03-09       Impact factor: 2.350

9.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.

Authors:  James L Chen; Daniel E Appelbaum; Masha Kocherginsky; Charles L Cowey; Wendy Kimryn Rathmell; David F McDermott; Walter M Stadler
Journal:  Cancer Med       Date:  2013-07-10       Impact factor: 4.452

10.  The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.

Authors:  Manabu Kakizoe; Masahiro Yao; Ukihide Tateishi; Ryogo Minamimoto; Daiki Ueno; Kazuhiro Namura; Kazuhide Makiyama; Narihiko Hayashi; Futoshi Sano; Takeshi Kishida; Kazuki Kobayashi; Sumio Noguchi; Ichiro Ikeda; Yoshiharu Ohgo; Masataka Taguri; Satoshi Morita; Tomio Inoue; Yoshinobu Kubota; Noboru Nakaigawa
Journal:  BMC Cancer       Date:  2014-06-02       Impact factor: 4.430
View more
  2 in total

Review 1.  Recent advances in imaging techniques of renal masses.

Authors:  Ankita Aggarwal; Chandan J Das; Sanjay Sharma
Journal:  World J Radiol       Date:  2022-06-28

2.  MicroRNA-384 inhibits nasopharyngeal carcinoma growth and metastasis via binding to Smad5 and suppressing the Wnt/β-catenin axis.

Authors:  Xinyu Zeng; Huiqun Liao; Fusen Wang
Journal:  Cytotechnology       Date:  2021-02-26       Impact factor: 2.058
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.